CalciMedica (NASDAQ:CALC – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14, Zacks reports.
CalciMedica Stock Performance
CALC stock opened at $1.99 on Friday. The firm has a market cap of $26.83 million, a P/E ratio of -1.84 and a beta of 1.20. The firm’s fifty day moving average is $2.38 and its 200 day moving average is $3.16. CalciMedica has a 52 week low of $1.83 and a 52 week high of $6.27.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research note on Tuesday, March 4th.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- 5 Top Rated Dividend Stocks to Consider
- MarketBeat Week in Review – 03/24 – 03/28
- What is a Bond Market Holiday? How to Invest and Trade
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- What Are Dividend Achievers? An Introduction
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
